Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
株式のランク #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
株価
$263.25
時価総額
$465.10B
変化(1日)
-0.68%
変化(1年)
18.26%
US
取引 AbbVie Inc. (ABBV)

カテゴリー

AbbVie Inc.(ABBV)の収益
Jun 2026 時点の収益 TTM: $64.39B
AbbVie Inc. の最新の財務報告によると、現在の収益 (TTM) は $64.39B です。2024 年には $56.33B の収益があり、これは 2023 年の $54.32B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
AbbVie Inc. の収益履歴(2009 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $64.39B 5.27%
2025 $61.16B 8.57%
2024 $56.33B 3.71%
2023 $54.32B -6.44%
2022 $58.05B 3.30%
2021 $56.20B 22.69%
2020 $45.80B 37.69%
2019 $33.27B 1.57%
2018 $32.75B 16.08%
2017 $28.22B 10.06%
2016 $25.64B 12.16%
2015 $22.86B 14.52%
2014 $19.96B 6.23%
2013 $18.79B 2.23%
2012 $18.38B 5.37%
2011 $17.44B 11.55%
2010 $15.64B 10.02%
2009 $14.21B 0.00%
同業他社の収益
企業 収益 収益の差
$79.67B 23.73%
US
$97.93B 52.10%
US
$77.52B 20.40%
CH
$66.40B 3.13%
US
$56.26B -12.62%
CH